Novartis AG (NVS) stock
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$159.13−1.07 (-0.67%)
Close on Nov 17, 2026Market cap $303.64BP/E 22.3Yield –
Novartis operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was $17.64B, up 21.3% from the year before. Over ten years it grew 7.0% a year on average. The highest annual figure on record is $17.64B in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.64B | +21.3% |
| FY2024 | Dec 31, 2024 | $14.54B | +48.9% |
| FY2023 | Dec 31, 2023 | $9.77B | +22.9% |
| FY2022 | Dec 31, 2022 | $7.95B | -21.0% |
| FY2021 | Dec 31, 2021 | $10.06B | -0.9% |
| FY2020 | Dec 31, 2020 | $10.15B | +11.7% |
| FY2019 | Dec 31, 2019 | $9.09B | +8.1% |
| FY2018 | Dec 31, 2018 | $8.40B | -3.4% |
| FY2017 | Dec 31, 2017 | $8.70B | +5.2% |
| FY2016 | Dec 31, 2016 | $8.27B | -7.9% |
| FY2015 | Dec 31, 2015 | $8.98B | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.75B | +113.2% |
| Q2 FY2025 | Jun 30, 2025 | $4.86B | +39.8% |
| Q2 FY2024 | Jun 30, 2024 | $4.01B | +70.7% |
| Q2 FY2023 | Jun 30, 2023 | $2.81B | +5.4% |
| Q2 FY2022 | Jun 30, 2022 | $2.23B | -8.4% |
| Q2 FY2021 | Jun 30, 2021 | $3.48B | +52.6% |
| Q2 FY2020 | Jun 30, 2020 | $2.35B | – |
| Q2 FY2019 | Jun 30, 2019 | $2.66B | – |
| Q2 FY2018 | Jun 30, 2018 | $2.43B | – |
| Q2 FY2017 | Jun 30, 2017 | $2.28B | – |
See a number that looks wrong?